Premium
Intra‐ocular pressure spike after Aflibercept and Ranibizumab intravitreal injections
Author(s) -
El Chehab H.,
Agard E.,
Russo A.,
Malcles A.,
Dot C.
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2015.0430
Subject(s) - ranibizumab , medicine , aflibercept , ophthalmology , intraocular pressure , significant difference , ocular hypertension , anesthesia , surgery , bevacizumab , chemotherapy
Purpose Since anti‐ VEGF sapproval, intra vitreous injections ( IVI ) represent a booming therapeutic delivery mode. Immediate ocular hypertension ( OHT ) induced is known after these IVI s. The purpose of this study is to compare the OHT after Aflibercept and Ranibizumab IVI . Methods In this prospective study, we compared 30 patients who received an Aflibercept IVI (0.05 mL) to 30 patients who received Ranibizumab for wet AMD . IVI were performed with a 30G needle pushed to the hilt with an anti‐reflux system. We measured intraocular pressure ( IOP ) using a portable aplanation tonometer PERKINS MK 2 (Haag‐Streit, Koeniz, Switzerland) before injection (T0), immediately after IVI (T1), 5 minutes (T5), 15 minutes (T15) and 45 minutes (T45) after the IVI . IOP were compared by a t‐test. Results In Aflibercept group, at T0, IOP was 13.4 mmHg + 1.5. All patients had a significant increase in IOP at T1 (42.7 mmHg + 3, p < 0.001). At T5, IOP decreased but was still statistically higher than baseline IOP (23.6 mmHg + 3.1, p < 0.001). At T15, IOP returned to normal values but was higher than T0 (16.2mm HG + 2.1, p = 0.009). At T45, IOP was 13 mmHg + 1.2, with no significant difference from baseline (p = 0.65). In Ranibizumab group, baseline IOP was 13.8 mmHg + 1.1. IOP increased at T1 (45.6 mmHg + 2.2, p < 0.001). At T5 and T15, IOP were still higher than baseline (24.6 mmHg + 2.2, p < 0.001 and 17.9 + 1.5, p < 0.001). At T45, IOP was 12.7 mmHg + 1.5, with no significant difference from baseline (p = 0.12). At each time measure, there is no statistically difference between two groups. Conclusions Aflibercept and Ranibizumab IVI induce an IOP spike for a short time. It seems to be equal between the two drugs and essentially related to the injected volume.